ARCT

Arcturus Therapeutics Holdings Inc. Common Stock

9.39

USD

-0.10

-1.05%

Nov 10, 15:59 UTC -5

Closed

After-Market

9.57

+0.18

+1.92%

Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Earnings

ARCT Earnings Reports

Positive Surprise Ratio

ARCT beat 28 of 43 last estimates.

65%

Next Report

Date of Next Report

Mar 01, 2027

Estimate for Q4 26 (Revenue/ EPS)

$5.09M

-$0.90

Implied change from Q3 26 (Revenue/ EPS)

-72.18%

+246.15%

Implied change from Q4 25 (Revenue/ EPS)

-29.27%

-12.62%

Arcturus Therapeutics Holdings Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, ARCT reported earnings of -0.26 USD per share (EPS) for Q3 26, beating the estimate of -0.69 USD, resulting in a 62.44% surprise. Revenue reached 18.30 million, compared to an expected 8.16 million, with a 124.28% difference. The market reacted with a +10.58% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.90 USD, with revenue projected to reach 5.09 million USD, implying an increase of 246.15% EPS, and decrease of -72.18% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Arcturus Therapeutics Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Arcturus Therapeutics Holdings Inc. Common Stock reported EPS of -$0.26, beating estimates by 62.44%, and revenue of $18.30M, 124.28% above expectations.

How did the market react to Arcturus Therapeutics Holdings Inc. Common Stock's Q3 2026 earnings?

The stock price moved up 10.58%, changed from $9.36 before the earnings release to $10.35 the day after.

When is Arcturus Therapeutics Holdings Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 01, 2027.

What are the forecasts for Arcturus Therapeutics Holdings Inc. Common Stock's next earnings report?

Based on -- analysts, Arcturus Therapeutics Holdings Inc. Common Stock is expected to report EPS of -$0.90 and revenue of $5.09M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.